Zephyr® Endobronchial Valve Treatment
The Outcomes, The Evidence, The Lives Changed
April 10, 2024
6:00 P.M. ET / 3:00 P.M. PT
Please join this webinar to learn more about the following:
- Treatment mechanism of action & patient experience
- Clinical evidence, patient outcomes, potential risks
- Patient eligibility and screening procedures
- Patient management strategies
Deborah Stahlnecker, DO, FCCP
Director, Interventional Pulmonary
Medical Director, Anderson ICU
St. Luke’s Pulmonary and Critical Care Associates
Thomas B. Zanders, DO, FACP
Program Director, Pulmonary & Critical Care Medicine Fellowship
Medical Director, Medical Intensive Care Unit Bethlehem Campus
St. Luke’s Pulmonary and Critical Care Associates
Please Register Below
The Zephyr Endobronchial Valve is a clinically-proven Bronchoscopic treatment for patients with severe COPD/emphysema who suffer from dyspnea despite optimized medical therapy.
Over 25,000 patients have been treated globally. The GOLD Report has included Endobronchial Valve Treatment an Evidence “A” intervention since 2020.
Physicians are paid consultants of Pulmonx Corporation.
© 2023 Pulmonx Corp or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates.
US-EN-1896-v2